Clinical trials: Regorafenib
Malignant Tumor
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
Advanced solid tumors remain a major therapeutic challenge due to their complex heterogeneity and the immunosuppressive tumor microenvironment (TME).
- Trial name
- NCT07567222
- Testing
- YMN101, YMN102, YMN103
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- West China Hospital
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Macular Degeneration
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4…
- Trial name
- DREAM (NCT02222207)
- Testing
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Ranibizumab
- Where
- 149 sites in United States, Australia and 16 more
- Volunteers
- 52 people
- Sponsor
- Bayer
CCR5, Microsatellite Stable
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)
- Conditions
- CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer
- Trial name
- NCT05730673
- Testing
- 700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2
- Sponsor
- CytoDyn, Inc.
Advanced and Metastatic Solid Tumor
Regorafenib and Nivolumab Simultaneous Combination Therapy
the efficacy and safety ofhe use of regorafenib in combination with nivolumab
- Trial name
- REGONIVO (NCT03406871)
- Testing
- Regorafenib, Nivolumab
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Kohei Shitara
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
Although immunotherapy-based therapies (including targeted-immunotherapy or dual-immunotherapy protocols) have become the first-line standard treatment for advanced hepatocellular carcinoma (HCC), there remains a lack of…
- Trial name
- NCT07501351
- Testing
- Intensified Therapy, Conversion Therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
This study will evaluate the addition of regorafenib to standard of care treatment with TMZ as adjuvant therapy, and in combination with TMZ+RT as concomitant therapy.
- Trial name
- REGOMA-2 (NCT06095375)
- Testing
- Regorafenib, Temozolomide
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
- Trial name
- NCT03994601
- Testing
- BMS-986288, Nivolumab, Regorafenib
- Where
- 40 sites in United States, Argentina and 5 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Meningioma, Malignant
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas.
- Trial name
- MIRAGE (NCT06275919)
- Testing
- Regorafenib 40 MG Oral Tablet, Local Standard of Care
- Where
- 20 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Metastatic Colorectal Cancer
Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting
This is a largest cohort study aimed to estimate the overall survival of patients been treated with regorafenib for metastatic colorectal cancer (mCRC) within the frame of a french compassionate program.
- Trial name
- REBECCA (NCT02310477)
- Testing
- regorafenib
- Where
- France
- Volunteers
- 704 people
- Sponsor
- Centre Oscar Lambret
Glioblastoma, Glioblastoma, IDH-wildtype
Biomolecular Analysis for Predicting Response to Regorafenib
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
- Trial name
- RegoRec (NCT05759195)
- Testing
- Biomolecular tumor analysis
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Colorectal Cancer (mCRC)
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
This is an observational study using data that has been collected from participants who received their usual treatments. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the…
- Trial name
- STAR-T (NCT05839951)
- Testing
- Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
- Where
- United States
- Volunteers
- 818 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Oligoprogression
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Approximately 70% of hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage, with no opportunity for curative treatments. For these patients, systemic therapies are the main treatment modalities.
- Trial name
- NCT06592612
- Testing
- SBRT and second-line systemic therapy, Second-line systemic therapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization, Regorafenib
- Trial name
- ROSE (NCT05811481)
- Testing
- TACE, Regorafenib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- WenBo Guo
Neoplasms
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe renal impairment when compared to the Control group (cancer subjects with normal or mildly impaired renal function)
- Trial name
- NCT01853046
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 9 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer (mCRC)
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer…
- Trial name
- NCT06089330
- Testing
- JMT101, SG001, Irinotecan
- Volunteers
- 102 people
- Sponsor
- Shanghai JMT-Bio Inc.
Carcinoma, Hepatocellular
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.
- Trial name
- NCT01003015
- Testing
- BAY73-4506
- Where
- 13 sites in Germany, Italy and 2 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Neoplasms
Safety and Effectiveness of Regorafenib
This study is a prospective observational cohort study. The study will be conducted in routine clinical practice settings. It is planned to enroll 1000 patients with metastatic Colorectal Cancer (mCRC) who have been previously…
- Trial name
- Correlate (NCT02042144)
- Testing
- Stivarga (Regorafenib, BAY73-4506)
- Where
- 13 sites in Argentina, Austria and 11 more
- Volunteers
- 1,034 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
This is an interventional, randomized open-label, parallel-group, multicenter, dose escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd line treatment in mCRC patients.
- Trial name
- NCT04008511
- Testing
- Regorafenib, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- China Medical University, China